Bajaj Healthcare Q2 FY27 Results: Standalone Net Profit ₹14.09 Crore on Total Income of ₹177 Crore

Earnings
Pharmaceuticals

Blacklitt Research17 October 20262 min read

A technician in a white coat working at laboratory glassware, in an old black-and-white photograph — State Government Photographer, via Wikimedia Commons (CC0 1.0). Illustrative image.

Bajaj Healthcare reported standalone total income of ₹176.79 crore and net profit of ₹14.09 crore for the quarter ended 30 Sep 2026.

Key highlights

Standalone

The company on its own, without its subsidiaries

Total income: ₹177 crore, up 18.2% YoY, up 6.2% QoQ
Net profit: ₹14.09 crore, up 26.8% YoY, up 2.8% QoQ
EPS: ₹4.19, against ₹3.53 in Q2 FY26
Net profit margin: 7.97%, against 7.43% a year earlier and 8.23% in June

Summary

Standalone ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	176.79	149.57	+18.2%	166.44	+6.2%
Revenue from operations	175.90	147.92	+18.9%	165.63	+6.2%
Other income	0.89	1.65	-46.1%	0.81	+9.9%
	14.09	11.11	+26.8%	13.70	+2.8%
Finance costs	5.98	5.56	+7.6%	6.09	-1.8%
Depreciation	7.65	7.08	+8.1%	7.01	+9.1%
Tax expense	4.10	3.51	+16.8%	2.57	+59.5%
Net profit margin	7.97%	7.43%	+0.54 pp	8.23%	-0.26 pp
Tax as share of profit before tax	22.2%	22.0%	+0.19 pp	15.6%	+6.57 pp
EPS, basic (₹)	4.19	3.53	+18.7%	4.07	+2.9%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Profit grew faster than revenue, but by less than the headline suggests for the cost lines. Revenue from operations rose 18.9% to ₹175.90 crore and net profit 26.8% to ₹14.09 crore. Other income fell 46.1% to ₹0.89 crore, depreciation rose 8.1% to ₹7.65 crore and finance costs 7.6% to ₹5.98 crore, so the extra profit came from the operating margin. Tax took 22.2% of profit before tax against 15.6% in June. Earnings per share were ₹4.19 against ₹3.53.

The notes cover disposals and an acquisition. The board had approved the sale of units at Tarapur and Bharuch as going concerns, and their assets are held for sale; on 23 June 2026 it approved the sale of its unit at Plot N-178, MIDC Tarapur, expected to conclude by 31 October 2026, and after the quarter the company completed the sale of a plot at Dahej, Bharuch. In April 2025 the company acquired Genrx Pharmaceuticals Private Limited (in liquidation), and the application for the takeover remained pending before the NCLT at 30 September 2026. The company reports one segment, pharmaceuticals.

Inference

Bajaj Healthcare's profit grew faster than revenue, and the company is selling several units that it has classified as held for sale.

The Genrx takeover is still before the NCLT, and the filing does not give the effect of the unit sales on later results.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Bajaj Healthcare Q2 FY27 Results: Standalone Net Profit ₹14.09 Crore on Total Income of ₹177 Crore

Key highlights

Standalone

Summary

Inference

Sign up to continue reading

Disclaimer:

Latest posts

Venus Pipes & Tubes Begins Commercial Production of Pipe Spooling on 20 October 2026

Crisil Reaffirms Uflex's AA-/Negative Rating on ₹4,600 Crore Bank Facilities

Moody's Affirms Yes Bank's Ba1 Deposit Rating With Stable Outlook After AT1 Ruling

Sterling and Wilson's South African Unit Sues Insurers Over ₹25.50 Crore Unpaid Bonds